S'abonner

Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting - 15/01/19

Doi : 10.1016/j.tube.2018.09.009 
Yuri F. van der Heijden a, b , Fareed Abdullah c , Bruno B. Andrade d, e, f, g, h, i , Jason R. Andrews j , Devasahayam J. Christopher k , Julio Croda l , Heather Ewing m , David W. Haas n, o , Mark Hatherill p , C. Robert Horsburgh q, r , Vidya Mave s, t , Helder I. Nakaya w , Valeria Rolla x , Sudha Srinivasan y , Retna Indah Sugiyono z , Cesar Ugarte-Gil aa, bb, cc, dd , Carol Hamilton ee,
a Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, TN, USA 
b Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA 
c Office of AIDS and TB Research, South African Medical Research Council, Pretoria, South Africa 
d Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, 40296-710, Brazil 
e Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, José Silveira Foundation, Salvador, 45204-040, Brazil 
f Wellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, 7925, South Africa 
g Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA 
h Universidade Salvador (UNIFACS), Laureate University, Salvador, Bahia, 41720-200, Brazil 
i Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, 40290-000, Brazil 
j Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA 
k Department of Pulmonary Medicine, Christian Medical College, Vellore, Tamilnadu, India 
l School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Brazil, Oswaldo Cruz Foundation, Campo Grande, Brazil 
m Vanderbilt University School of Medicine, Nashville, TN, USA 
n Departments of Medicine, Pharmacology, Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA 
o Department of Internal Medicine, Meharry Medical College, Nashville, TN, USA 
p South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, South Africa 
q Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA 
r Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, USA 
s Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India 
t Johns Hopkins University School of Medicine, Baltimore, MD, USA 
w Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil 
x Clinical Research Laboratory on Mycobacteria, National Institute of Infectious Diseases Evandro Chagas, Fiocruz, Brazil 
y Division of AIDS, National Institute of Allergy and Infectious Diseases at the National Institutes of Health, Bethesda, MD, USA 
z INA-RESPOND, National Institute of Health Research and Development, Ministry of Health, Indonesia 
aa Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru 
bb School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru 
cc TB Centre, London School of Hygiene and Tropical Medicina, London, UK 
dd Department of International Health, Johns Hopkins Bloomberg School of Public Health, Maryland, USA 
ee FHI 360 and Duke University, Durham, NC, USA 

Corresponding author. FHI 360 and Duke University, Durham, NC, USA.FHI 360 and Duke UniversityDurhamNCUSA

Abstract

RePORT International is a global network of research sites in India, Brazil, Indonesia, South Africa, China, and the Philippines dedicated to collaborative tuberculosis research in the context of HIV. A standardized research protocol (the Common Protocol) guides the enrollment of participants with active pulmonary tuberculosis and contacts into observational cohorts. The establishment of harmonized clinical data and bio-repositories will allow cutting-edge, large-scale advances in the understanding of tuberculosis, including identification of novel biomarkers for progression to active tuberculosis and relapse after treatment. The RePORT International infrastructure aims to support research capacity development through enabling globally-diverse collaborations. To that end, representatives from the RePORT International network sites, funding agencies, and other stakeholders gathered together in Brazil in September 2017 to present updates on relevant research findings and discuss ideas for collaboration. Presenters emphasized research involving biomarker identification for incipient tuberculosis, host immunity and pharmacogenomics, co-morbidities such as HIV and type 2 diabetes mellitus, and tuberculosis transmission in vulnerable and high-risk populations. Currently, 962 active TB participants and 670 household contacts have contributed blood, sputum, urine and microbes to in-country biorepositories. Cross-consortium collaborations have begun sharing data and specimens to analyze molecular and cytokine predictive patterns.

Le texte complet de cet article est disponible en PDF.

Keywords : Transmission, Pharmacogenomics, Incipient tuberculosis, HIV, Diabetes, Biomarkers

Abbreviations : DAIDS, NIAID, NIH, TB, RePORT, WHO, HIV, MDR-TB, INA-RESPOND, DM, ART, FDC, NNRTI, PI, DNA, Cmax, PGE2, LMIC, RNA, qRT-PCR, GPS


Plan


© 2018  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 113

P. 153-162 - décembre 2018 Retour au numéro
Article précédent Article précédent
  • Cell death at the cross roads of host-pathogen interaction in Mycobacterium tuberculosis infection
  • Krishnaveni Mohareer, Suman Asalla, Sharmistha Banerjee
| Article suivant Article suivant
  • The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection
  • Musa Marimani, Aijaz Ahmad, Adriano Duse

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.